We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Quantum-Dot Based Method Detects Early Signs of Cancer

By LabMedica International staff writers
Posted on 21 Aug 2009
Using tiny crystals called quantum dots scientists developed a sensitive test to find DNA attachments that frequently are early warning signs of cancer. The test, which detects both the presence and the quantity of DNA changes, could alert people who are at risk of developing the disease and also help monitor certain cancer treatments.

The target of the nanotechnology assay, called mass spectrometry quantum dot fluorescence resonance energy transfer (MS-qFRET), was DNA methylation, which occurred when a methyl group called attached itself to cytosine, one of the four nucleotides of DNA. When methylation occurred at critical gene locations, it halted the release of proteins that suppress tumors, making it easier for cancer cells to form and multiply. The methylation changes also appeared to be an early event that precedes the appearance of genetic mutations, another precursor to cancer.

A study, which included the detection of DNA markers in sputum from lung cancer patients, was designed to show that the nanotechnology was sound. Compared to current methods, the test appeared to be more sensitive and delivered results more quickly. "The technique looks terrific, but it still needs to be tested in many real-world scenarios," Stephen B. Baylin, M.D., deputy director of the Johns Hopkins Kimmel Cancer (Baltimore, MD, USA) and a coauthor of the study said, "Some of these studies are already under way here. If we continue to see exciting progress, this testing method could easily be in wide use within the next five years."

The study was published in the August 2009 edition of the journal Genome Research.

Related Links:
Johns Hopkins Kimmel Cancer


New
Gold Member
Thyroid Stimulating Hormone Assay
TSH EIA 96 Test
Unit-Dose Packaging solution
HLX
New
Hemacytometer Cover Glasses
Propper Hemacytometer Cover Glasses
New
Automated Nucleic Acid Extraction Instrument
EX9600

Latest Molecular Diagnostics News

Early Blood Test Predicts Survival in Patients with Metastatic Prostate Cancer

POC Sepsis Test Delivers Fast, Accurate and User-Friendly Results in Critical Care Settings

Experimental Blood Test Improves Detection of Early-Stage Pancreatic Cancer